About 300 million people worldwide experience depression. Many symptoms underline their experience, with disturbed sleep being a common pattern. However, not enough research goes into unearthing if people with sleep disorders are suffering from more than just that. That’s where mental health tech company Medibio Limited (ASX: MEB) comes in. The Company has achieved a
Read More
(Not so) fun fact for your Thursday morning: sleep deprivation was (and I’m sure, still is) used as a form of torture. One of the “enhanced interrogation techniques” the CIA used in the wake of the 9/11 terrorist attacks was just that. Lack of sleep disrupts biological functions deep in the brain. Whilst not as
Read More
Mental illness will have an impact on 45% of Australians at some point in their lifetime. While the world is becoming increasingly aware of mental health conditions, little is being done to redefine the diagnostics. Currently, the gold standard in the diagnosis of mental illness is The Diagnostic and Statistical Manual of Mental Disorders (DSM5).
Read More
Analysing biometric data of an individual between night and day, medtech company Medibio (ASX: MEB) is set to offer solutions to better manage the mental health of users through an app, aiming to monitor stress levels and improve them over time. The app will be supported by a biometric wearable divide such as a Garmin
Read More
Mental health medtech company Medibio (ASX: MEB) has continued its accelerated plans towards FDA approvals under new management with the company having lodged an FDA application overnight for their mental health screening software – MEBsleep. Having collected the required clinical data MEBsleep (previously named STAGER) tested more than 1,000 individuals using Medibio’s sleep staging algorithm
Read More
With mental health issues continuing to make headlines as greater importance is placed on its value towards wellbeing, medtech company Medibio (ASX: MEB) is developing a Software Medical Device for early detection of depressive symptoms. Sleep disorders, their onset, and progression, will be the key depressive symptom being targeted by Medibio’s technology which will be
Read More